Antibody Titers against Canine Parvovirus Type 2 in Vaccinated Dogs Attending Veterinary Clinics | ||
| Journal of Applied Veterinary Sciences | ||
| Volume 10, Issue 4, October 2025, Pages 84-88 PDF (296.05 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/javs.2025.415843.1712 | ||
| Authors | ||
| Raúl Hernández; Carlos Aguilar; Judyana Aguirre; Luis M Salinas; Byron Flores* | ||
| Universidad Internacional Antonio de Valdivieso, 47000, Rivas, Nicaragua | ||
| Abstract | ||
| Canine parvovirus type 2 (CPV-2) represents one of the main challenges in veterinary clinical practice. Despite the availability of several commercial vaccines, morbidity and mortality continue to affect even vaccinated puppies. The aim of this study was to evaluate antibody titers against CPV-2 in vaccinated dogs attending veterinary clinics in Nicaragua. A total of 27 dogs aged 3 to 10 months were analyzed. Hemagglutination Inhibition (HI) assays were performed to determine antibody titers. Hematological parameters were measured, and vaccination histories were collected. Among the 27 dogs, 4 (14.8%) had antibody titers of 1:16, 6 (22.2%) had titers of 1:2, 3 (11.1%) had titers of 1:4, 7 (25.9%) had titers of 1:8, and 7 (25.9%) were seronegative. A significant difference was observed in mean corpuscular hemoglobin (MCH) (p = 0.043) between dogs with titers of 1:16 and seronegative dogs, with the latter showing higher MCH values compared to the other groups. Vaccine type and number of doses were associated with titer levels, with better responses observed in dogs that completed the full three-dose schedule. Overall, low levels of antibodies against CPV-2 were found in dogs that had received prior vaccination against this pathogen. These findings emphasize how important it is to monitor vaccination protocols in resource-limited regions. | ||
| Keywords | ||
| Antibody; Canine parvovirus; Immunity; Vaccine | ||
| References | ||
|
CUNHA RDS, D.A., SILVA JUNIOR C.L., COSTA C.A., DE AGUIAR H.M., and JUNQUEIRA JÚNIOR D.G., 2020. Comparison of immunity against canine distemper, adenovirus and parvovirus after vaccination with two multivalent canine vaccines. Vet Med Sci 6:330–334. https://onlinelibrary.wiley.com/doi/abs/10.1002/vms3.274
DE CRAMER, K.G.M., STYLIANIDES, E., and VAN VUUREN, M., 2011. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. Vet Microbiol 149:126–132. https://www.sciencedirect.com/science/article/pii/S037811351000516X
ELLIS, J., MARZIANI, E., AZIZ, C., COHN, L.A., LEA, C., MOORE, G.E., and TANEJA, N., 2022. AAHA Canine Vaccination Guidelines.
ESCOBAR PINEDA, K., MARTÍNEZ CASTAÑEDA, J.S., ESCOBAR PINEDA, K., and MARTÍNEZ CASTAÑEDA, J.S., 2022. Títulos de anticuerpos IgG protectores obtenidos a través de vacunación o infección no protegen contra parvovirus canino tipo 2C en perros. Universidad Nacional Mayor de San Marcos. Rev Investig Vet Perú 33. http://www.scielo.org.pe/scielo.php?script=sci_abstract&pid=S1609-91172022000600023&lng=es&nrm=iso&tlng=es
FLORES, B., MAIRENA, J., GUTIÉRREZ, J., SHELEBY-ELÍAS, J., FUERTES, N.H,, HALAIHEL, K. N., FLORES, B., MAIRENA, J., GUTIÉRREZ, J., SHELEBY-ELÍAS J., et al., 2020. Identificación de parvovirus canino tipo 2C en cachorros de Nicaragua. Universidad de Córdoba, Montería, Colombia. Rev MVZ Córdoba 25:11–16. http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0122-02682020000200011&lng=en&nrm=iso&tlng=es
HOARE, C.M., DEBOUCK, P., and WISEMAN, A., 1997. Immunogenicity of a low-passage, high-titer modified live canine parvovirus vaccine in pups with maternally derived antibodies. Vaccine 15:273–275. https://www.sciencedirect.com/science/article/pii/S0264410X96001843
RUBIO, A., MARTÍNEZ ÁVILA, R., GUZMÁN ITURBE, H., CHÁVEZ ZAPATA, F., DE LA COLINA, G., SALAZAR GUEVARA, J., RAMÍREZ, I.A., AUTRÁN DE MORAIS, H., and GUERRERO, J., 2018. Guías para la vacunación de perros (caninos) y gatos (felinos) en Perú. Universidad Nacional Mayor de San Marcos. Rev Investig Vet Perú 29:1463–1474. http://www.scielo.org.pe/scielo.php?script=sci_abstract&pid=S1609-91172018000400043&lng=es&nrm=iso&tlng=pt
SCHUMANN, S., BAQUERO-PEREZ, B., and WHITEHOUSE, A., 2016. Interactions between KSHV ORF57 and the novel human TREX proteins, CHTOP and CIP29. Microbiology Society,. J Gen Virol 97:1904–1910. https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000503
SQUIRES, R.A, CRAWFORD, C., MARCONDES, M., and WHITLEY, N., 2024. Guidelines for the vaccination of dogs and cats – compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). J Small Anim Pract 65:277–316. https://onlinelibrary.wiley.com/doi/abs/10.1111/jsap.13718
THRALL, M.A., WEISER, G., ALLISON,R.W., and CAMPBELL, T.W., 2012. Veterinary Hematology and Clinical Chemistry. John Wiley & Sons, 37 pp.
VARGAS OROZCO, C., and BEDOYA OSORIO, A.L., 2021. Parvovirus canina en Latinoamérica. Pereira: Universidad Tecnológica de Pereira. https://hdl.handle.net/11059/13819
WILKES, R.P. 2023. Canine Distemper Virus in Endangered Species: Species Jump, Clinical Variations, and Vaccination. Multidisciplinary Digital Publishing Institute. Pathogens 12:57. https://www.mdpi.com/2076-0817/12/1/57
WILSON, S., ILLAMBAS, J., SIEDEK, E., STIRLING, C., THOMAS, A., PLEVOVÁ, E., STURE, G., and SALT, J., 2014. Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c. Vaccine 32:5420–5424. https://www.sciencedirect.com/science/article/pii/S0264410X14010846
| ||
|
Statistics Article View: 84 PDF Download: 19 |
||
